Navigation Links
bioMerieux Adds Methicillin-resistant Staphylococcus aureus (MRSA) Screening Tool to its Arsenal
Date:10/28/2009

DURHAM, N.C., Oct. 28 /PRNewswire/ -- bioMerieux - a world leader in the field of in vitro diagnostics - today announced the U.S. launch of chromID MRSA, a simple and cost-effective solution in the struggle against MRSA. The product recently received FDA 510(k) clearance for the detection of MRSA, one of the most pervasive sources for high-morbidity healthcare-associated infections (HAI) in U.S. hospitals.(1) The current national debate on escalating healthcare costs includes screening for multi-drug resistant bacteria, such as MRSA. chromID MRSA is perfectly adapted for general screening processes in healthcare institutions as it economically provides unambiguous results with a simple protocol. The presence of MRSA is visually identified by green colored colonies on chromID MRSA chromogenic media (biomerieux-usa.com/chromid) after a 24-hour incubation period.

"According to CDC data, invasive MRSA infections occur in approximately 94,000 people annually and cause as many as 9,000 deaths per year," said Herb Steward, general manager and executive vice president, bioMerieux North America. "Helping healthcare facilities to cost-effectively detect antibiotic-resistant strains with improved accuracy can play a critical role in the bigger picture of decreasing MRSA-related nosocomial infections," said Steward.

As a leader in Microbiology, it is bioMerieux's objective to provide customers with the most flexible and complete solution to effectively manage MRSA, spanning manual and automated techniques, from culture-based methods to molecular biology. A more comprehensive approach to containing MRSA needs to be taken, involving critical functions such as resistance detection, organism strain typing for outbreak investigations, hygiene, and antibiotic stewardship programs.

"We applaud organizations like bioMerieux for playing a key role on World MRSA Day and for bringing cost-effective solutions to our healthcare facilities," said Jeanine Thomas, MRSA survivor and founder of the MRSA Survivors Network. Thomas recently hosted the Inaugural World MRSA Day with a remembrance ceremony for those who have lost their lives or suffered from this preventable disease. Thomas added, "MRSA survivors, their families, and all those touched by this disease finally had their day and their voices heard."

A recent study published in Clinical Infectious Diseases examined the hospital and societal costs of antimicrobial-resistant infections (ARIs) in a Chicago teaching hospital.(2) Nearly half (43%) of the patients with antibiotic-resistant infections in the study had an infection due to MRSA. The paper also discussed the need for a more comprehensive evaluation of the cost of resistance and the potential economic benefits of prevention programs like antibiotic stewardship.

chromID MRSA simplifies the detection of MRSA, enabling more economical implementation of adapted prevention measures. chromID MRSA agar is a selective and differential chromogenic medium for the qualitative detection of nasal colonization of methicillin-resistant S. aureus. This tool aids in the prevention and control of MRSA infections in healthcare settings. bioMerieux's chromID MRSA has been widely adopted throughout Europe over the past few years, leading to more than two dozen publications in peer-reviewed journals and international conferences.

Identifying resistance and helping clinicians get clear actionable information so they can begin effective antibiotic therapy as early as possible is an integral part of bioMerieux's recently launched S.M.A.R.T. Campaign (biomerieux-usa.com/smart). The Solutions to Manage the Antimicrobial Resistance Threat (S.M.A.R.T.) initiative promises to create more educational resources for the lab and to provide healthcare professionals with relevant tools to identify, monitor, prevent, and track resistance.

References:

(1) Marchaim D. et al. The burden of methicillin-resistance Staphylococcus aureus infections on patients hospitalized in the US. 46th ICAAC meeting, San Francisco (USA), September 28, 2006 Abstract K-791

(2) Roberts R. et al. Hospital and Societal Costs of Antimicrobial-Resistant Infections in a Chicago Teaching Hospital: Implications for Antibiotic Stewardship. CID 2009:49 (15 October)

About MRSA Survivors Network

MRSA Survivors Network is a nonprofit organization comprised of volunteers dedicated to raising awareness for MRSA, campaigning for change, and giving vital support to those who have been afflicted with MRSA or lost loved ones.

MRSA Survivors Network was founded in 2003 by Jeanine Thomas, a survivor of MRSA, sepsis osteomylitis, and C. difficile. She became critically ill and nearly died from ankle surgery. Because of her experience, she has dedicated herself to raise awareness, campaign for new laws, and give support to those whose lives have been affected by MRSA.

Jeanine Thomas was the first patient advocate in the U.S. to raise alarm about MRSA and healthcare-acquired infections. MRSA Survivors Network has initiated groundbreaking legislation in the state of Illinois and works with other advocates in other states and on a federal level. MRSA Survivors Network partners with advocates in the UK and other countries to formulate global alliances to raise awareness for MRSA and antimicrobial resistance.

About bioMerieux

Advancing Diagnostics to Improve Public Health

A world leader in the field of in vitro diagnostics for 45 years, bioMerieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2008, revenues reached euro 1.111 billion with 84% of sales outside of France.

bioMerieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical, and cosmetic products. bioMerieux is listed on the NYSE Euronext Paris market (Code: BIM - Code ISIN: FR0010096479). Other information can be found at www.biomerieux-usa.com.

SOURCE bioMerieux


'/>"/>
SOURCE bioMerieux
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Shows Use of AdvanDxs PNA FISH(TM) Test was Associated with an 82% Reduction in Intensive Care Unit Mortality Rates from Staphylococcus aureus Bloodstream Infections
2. Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)
3. Cepheid Launches New GeneXpert(R) Tests in Europe for Simultaneous, Rapid Detection of Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus
4. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
5. Oral Cancer Foundation to Donate Screening Devices to Free Clinics
6. Study Suggests Vitamin D Screening and Appropriate Supplementation Indicated for All Cancer Patients
7. EAU Position Statement on Screening for Prostate Cancer
8. Leader in Prostate Health Urges Prostate Cancer Screening in Face of Contradicting Data
9. PSA Screening Cuts Deaths by 20%, Says Worlds Largest Prostate Cancer Study
10. Data Suggests New Antigen-Antibody Combo Test Useful for High Volume Public Health Screening
11. Lenetix Launches Screening Study of New Down Syndrome Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016 F ast ... answers at the point ... of scientific, technical and medical information products and services, has launched a ... reviewed clinical information via a mobile device. Elsevier designed the mobile app ... The new app is available in Android and iOS ...
(Date:2/11/2016)... investment" by Bruce Montgomery , one of this area,s most prominent biotech executives, and his ... , PhD. Photo - http://photos.prnewswire.com/prnh/20160211/332242 ... ... ... Kawas said the round was intended to be an $8 million raise but ...
(Date:2/11/2016)...  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) today ... the 38th annual John A. Boswick , ... being held February 14-18, 2016 in Hawaii ... in wound healing, burn care, and infection control, and ... Burns Association, Academy of Physicians in Wound Care and ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 12, 2016 , ... The Journal of Pain ... 0.416 in 2013. The SJR uses data taken from the Scopus database (Elsevier B.V.) ... number of citations received by the journal over a three year period and also ...
(Date:2/11/2016)... ... ... Hall Integrative Health and Chiropractic, PC which focuses on ... in March. All seven practices are set to start accepting patients in March ... According to this 2011 CNN article it is possible: http://www.cnn.com/2011/HEALTH/01/28/reverse.diabetes/ . Current ...
(Date:2/11/2016)... DC (PRWEB) , ... February 11, 2016 , ... ... an upcoming Feb. 23 webinar, “Intel’s Direct-to-Employee Benefit Model: A Case Study for ... not-for-profit Catholic health care system that’s partnering with Intel on value-based health benefits ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... as General Counsel. Garrett will focus on contract negotiations, corporate strategy and healthcare ... security law, and best practices in data breaches for the Part D Star ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... updated its hallmark resource, Infusion Therapy Standards of Practice, to include vascular visualization ... illumination with an estimated 85% share of the market, facilitates adherence to this ...
Breaking Medicine News(10 mins):